The US Food and Drug Administration (FDA), European Medicines Agency (EMA), and
Pharmaceuticals and Medical Devices Agency (PMDA) guidances on small‐molecule drug …

An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is
associated with adverse pregnancy outcomes and all HIV-positive pregnant women …

The purpose of this literature review is to comprehensively summarize changes in the
expression of phase II drug-metabolizing enzymes and drug transporters in both the …

The transport of drugs across the placenta is a point of great importance in pharmacotherapy
during pregnancy. However, the knowledge of drug transport in pregnancy is mostly based …

Selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake
inhibitors (SNRIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs) …

Medication use during pregnancy in the absence of pharmacokinetic and safety data is
common, particularly for antiretrovirals, as pregnant women are not usually included in …

The placenta is the only organ linking two different individuals, mother and fetus, termed as
blood-placental barrier. The functions of the blood-placental barrier are to regulate material …

Introduction Nucleoside analogs are an important class of antiviral agents. Due to the high
hydrophilicity and limited membrane permeability of antiviral nucleoside/nucleotide analogs …

Pregnancy alters the disposition and exposure to multiple drugs indicated for pregnancy-
related complications. Previous in vitro studies have shown that pregnancy-related …

Emtricitabine (FTC) is a first-line antiviral drug recommended for the treatment of AIDS
during pregnancy. We hypothesized that transporters located in the placenta contribute to …